mRNA– tag –
-
AATD Treatment Race Intensifies: Beam Therapeutics Plans Pivotal Cohort for Accelerated Approval of Base Editor BEAM-302
CRISPR Medicine News USA Overview The field of Alpha-1 Antitrypsin Deficiency (AATD) treatment is witnessing heightened competition, with five gene editing companies reporting new data and Sanofi introducing a non-edited recombinant prot... -
Cell-Free Advantage: Exosome-Biomaterial Platforms Offer Safer Treatment for Diabetic Skin Infections, But Clinical Translation Remains Complex
International Journal of Nanomedicine (論文) Global Overview A recent review explores exosome-biomaterial platforms as a promising, safer alternative to cell therapies for diabetic skin infections. These 'cell-free' approaches address sa... -
Engineered Exosomes Breach Blood-Brain Barrier, Unlocking New Vistas in Neuro-Oncology
MDPI (論文) Global Overview The blood-brain barrier (BBB) critically impedes drug delivery to the brain, posing a major challenge for treating central nervous system diseases, particularly brain tumors. Engineered exosomes are emerging a... -
University of Houston Researchers Discover Salt Significantly Enhances Lipid Nanoparticle Delivery Efficiency in Gene Therapy
University of Houston USA Overview University of Houston researchers have discovered that adding salt to lipid nanoparticles (LNPs) dramatically improves the intracellular delivery efficiency of mRNA vaccines and gene therapeutics. This ... -
PwC Report: Biopharma Ecosystem Fully Recovers with 16 M&A Deals Over $1B in Q1 2026, Driven by Next-Gen Modalities and GLP-1 Expansion
Fierce Pharma USA Overview A recent PwC report indicates the biopharma ecosystem has 'returned to full health,' with 16 M&A transactions exceeding $1 billion in Q1 2026. Deals primarily focused on 'differentiated science, GLP-1 expan... -
Pharmaceutical and Biotech M&A Surges in 2026, Driven by Pipeline Reinforcement and Expansion into Emerging Therapeutic Areas
DistilINFO Publications USA Overview The pharmaceutical and biotechnology sectors are experiencing a significant surge in M&A activity in 2026, as major drugmakers actively seek to fortify their pipelines and expand into novel therap... -
UT MD Anderson Develops Exosome-Based Therapy for Duchenne Muscular Dystrophy, Delivering Full-Length DMD mRNA to Dramatically Restore Muscle Function In Vivo
Nature Biomedical Engineering (via The University of Texas MD Anderson Cancer Center) USA Overview Researchers at The University of Texas MD Anderson Cancer Center have developed a novel therapeutic platform utilizing engineered extracel... -
Broad Institute Achieves Major Breakthrough in Prime Editing: Enhanced In Vivo Delivery with Optimized LNPs Paves Way for Broader Genetic Disease Therapies
Broad Institute USA Overview Researchers at the Broad Institute have significantly improved the efficiency and specificity of prime editing by optimizing its core components and developing an advanced lipid nanoparticle (LNP) delivery sy... -
T-CURX Acquires Germany’s Pantherna Therapeutics to Accelerate LNP-Based In Vivo CAR-T Therapy Development; United Immunity Also Enters In Vivo CAR-M Therapy for Solid Tumors and Fibrotic Diseases
HealthcareNOWradio.com Germany Overview T-CURX acquired Germany-based Pantherna Therapeutics, specializing in mRNA engineering and lipid nanoparticle (LNP) delivery technology, aiming to accelerate in vivo CAR-T therapy development and c... -
Cartesian Therapeutics Licenses WestGene LNP Technology, Initiates Phase 1 for In Vivo CAR-T Descartes-08 in Myasthenia Gravis, Streamlining Manufacturing
Biospace USA Overview Cartesian Therapeutics announced a strategic licensing agreement with WestGene Biopharma to accelerate its in vivo CAR-T platform development using WestGene’s targeted lipid nanoparticle (LNP) technology. This colla...
